probe-type-ii-band-alignment-one-dimensional-van-der-waals

Probe Type II Band Alignment in One-Dimensional Van Der Waals Heterostructures Using First-Principles Calculations

Computational tools based on density-functional theory (DFT) enable the exploration of the qualitatively new, experimentally attainable nanoscale ...

Ocean University of China

Actin-binding protein capping protein gelsolin-like (CapG) was preferentially expressed in human pulmonary arterial smooth muscle cells (PASMCs) under hypoxia, and reduced CapG expression was accompanied by impaired migration ability in vitro. We intended to investigate the effects of CapG on rat PASMCs and hypoxia-induced pulmonary hypertension (HPH) rat model.

Involvement of CapG in proliferation and apoptosis of pulmonary arterial smooth muscle cells and in hypoxia-induced pulmonary hypertension rat model.

Lung cancer is a common malignant cancer. Kirsten rat sarcoma oncogene (KRAS) mutations have been considered as a key driver for lung cancers. KRAS p.G12C mutations were most predominant in NSCLC which was comprised about 11-16% of lung adenocarcinomas (p.G12C accounts for 45-50% of mutant KRAS). But it is still not clear how the KRAS mutation triggers lung cancers. To study the molecular mechanisms of KRAS mutation in lung cancer. We analyzed the gene expression profiles of 156 KRAS mutation samples and other negative samples with two stage feature selection approach: (1) minimal Redundancy Maximal Relevance (mRMR) and (2) Incremental Feature Selection (IFS). At last, 41 predictive genes for KRAS mutation were identified and a KRAS mutation predictor was constructed. Its leave one out cross validation MCC was 0.879. Our results were helpful for understanding the roles of KRAS mutation in lung cancer.

The Functional Effects of Key Driver KRAS Mutations on Gene Expression in Lung Cancer.

Gefitinib (GEB) is one of the drugs used for patients with epidermal growth factor receptor (EGFR)-positive mutations in non-small cell lung cancer (NSCLC). However, application of GEB is limited by its low water solubility, stability, and utilization rate, especially the side effects while GEB is given by oral. In this study, nanoliposome was used as a carrier to prepare nanoliposome compound drug (GL) by embedding GEB in the nanoliposome perfectly combined with green nontoxic solvent and thin-film dispersion method. The nanoliposome structure was expected to improve the water solubility and biocompatibility of GEB, thus improving the effect of cancer treatment. The surface electronegative nanoliposomes can effectively avoid protein adsorption and prolong the circulation time . Meanwhile, the ratio of lecithin to cholesterol (LE/CH) was explored to maximize the encapsulation efficiency of nanoliposome. Subsequent test results showed that GL exhibited better stability, smaller particle size and higher encapsulation efficiency. In addition,  drug release curve also further confirmed that GL had a promising drug sustained-release effect. In particular, a series of  tests such as cell activity, apoptosis, colony formation, scratch, invasion, and cell cycle assays were performed. The results indicated that GL significantly enhanced the pro-apoptotic effect on A549 cells. Most cell cycles of A549 cells were blocked in the G0/G1 phase influenced by GL, thus inhibiting the proliferation of cancer cells.  anti-tumor studies showed that compared with pure GEB, GL had a significant inhibiting effect on NSCLC. In conclusion, the GL which was synthesized by a simple method in this study significantly improved the treatment effect of cancer cells, which proved that the nanoliposome carrier had an excellent application prospect in the treatment of lung cancer.

Gefitinib encapsulation based on nano-liposomes for enhancing the curative effect of lung cancer.

The tow-pore domain (KCNK) potassium channel family is associated with tumor progression, but its prognostic value in lung adenocarcinoma (LUAD) remains unclear. In this study, we integrated data from the TCGA and GEO databases to identify 9 KCNK-related differentially expressed genes, and based on this, we classified two molecular subtypes with significantly different prognoses. A 11-gene prognostic model with independent prognostic value was constructed through regression analysis. Immuno-analysis revealed that the low-risk group had stronger immune infiltration and might be more suitable for immunotherapy. These findings reveal the prognostic significance of the KCNK genes and provide a reference for immunotherapy.

Article	Year
Involvement of CapG in proliferation and apoptosis of pulmonary arterial smooth muscle cells and in hypoxia-induced pulmonary hypertension rat model. Experimental lung research\| PubMed ID: 27093378	2016
The Functional Effects of Key Driver KRAS Mutations on Gene Expression in Lung Cancer. Frontiers in genetics\| PubMed ID: 32117436	2020
Gefitinib encapsulation based on nano-liposomes for enhancing the curative effect of lung cancer. Cell cycle (Georgetown, Tex.)\| PubMed ID: 33300430	2020
Prognostic model based on KCNK family genes for predicting prognosis and immunotherapy response in lung adenocarcinoma patients. Computer methods in biomechanics and biomedical engineering\| PubMed ID: 40717588	2025

HuiHui Hu

Biography

JoVE Journal Publications

Other Publications